|
1
|
Rodrigues-Lisoni FC, Peitl P Jr, Vidotto
A, Polachini GM, Maniglia JV, Carmona-raphe J, Cunha BR, Henrique
T, Souza CF, Teixeira RA, et al Head and Neck Genome Project
GENCAPO: Genomics and proteomics approaches to the study of
cancer-stroma interactions. BMC Med Genomics. 3:142010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xing F, Saidou J and Watabe K: Cancer
associated fibroblasts (CAFs) in tumor microenvironment. Front
Biosci (Landmark Ed). 15:166–179. 2010. View Article : Google Scholar
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kawashiri S, Tanaka A, Noguchi N, Hase T,
Nakaya H, Ohara T, Kato K and Yamamoto E: Significance of stromal
desmoplasia and myofibroblast appearance at the invasive front in
squamous cell carcinoma of the oral cavity. Head Neck.
31:1346–1353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Woolard J, Wang WY, Bevan HS, Qiu Y,
Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E,
Perrin R, et al: VEGF165b, an inhibitory vascular endothelial
growth factor splice variant: Mechanism of action, in vivo effect
on angiogenesis and endogenous protein expression. Cancer Res.
64:7822–7835. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soker S, Takashima S, Miao HQ, Neufeld G
and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor
cells as an isoform-specific receptor for vascular endothelial
growth factor. Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ladomery MR, Harper SJ and Bates DO:
Alternative splicing in angiogenesis: The vascular endothelial
growth factor paradigm. Cancer Lett. 249:133–142. 2007. View Article : Google Scholar
|
|
8
|
Nowak DG, Amin EM, Rennel ES,
Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ,
Woolard J, Ladomery MR, et al: Regulation of vascular endothelial
growth factor (VEGF) splicing from pro-angiogenic to
anti-angiogenic isoforms: A novel therapeutic strategy for
angiogenesis. J Biol Chem. 285:5532–5540. 2010. View Article : Google Scholar :
|
|
9
|
Rennel ES, Hamdollah-Zadeh MA, Wheatley
ER, Magnussen A, Schüler Y, Kelly SP, Finucane C, Ellison D,
Cebe-Suarez S, Ballmer-Hofer K, et al: Recombinant human VEGF165b
protein is an effective anti-cancer agent in mice. Eur J Cancer.
44:1883–1894. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varey AH, Rennel ES, Qiu Y, Bevan HS,
Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, et
al: VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and
inhibits bevacizumab treatment in experimental colorectal
carcinoma: Balance of pro- and antiangiogenic VEGF-A isoforms has
implications for therapy. Br J Cancer. 98:1366–1379. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tayama M, Furuhata T, Inafuku Y, Okita K,
Nishidate T, Mizuguchi T, Kimura Y and Hirata K: Vascular
endothelial growth factor 165b expression in stromal cells and
colorectal cancer. World J Gastroenterol. 17:4867–4874. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsukamoto H, Kondo S, Mukudai Y, Nagumo T,
Yasuda A, Kurihara Y, Kamatani T and Shintani S: Evaluation of
anticancer activities of benzo[c]phenanthridine alkaloid
sanguinarine in oral squamous cell carcinoma cell line. Anticancer
Res. 31:2841–2846. 2011.PubMed/NCBI
|
|
13
|
Li C, Yazawa K, Kondo S, Mukudai Y, Sato
D, Kurihara Y, Kamatani T and Shintani S: The root bark of Paeonia
moutan is a potential anticancer agent in human oral squamous cell
carcinoma cells. Anticancer Res. 32:2625–2630. 2012.PubMed/NCBI
|
|
14
|
Sobin LH and Fleming ID: TNM
Classification of Malignant tumors, Fifth Edition. Union
International Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anneroth G, Batsakis J and Luna M: Review
of the literature and a recommended system of malignancy grading in
oral squamous cell carcinomas. Scand J Dent Res. 95:229–249.
1987.PubMed/NCBI
|
|
16
|
Perrin RM, Konopatskaya O, Qiu Y, Harper
S, Bates DO and Churchill AJ: Diabetic retinopathy is associated
with a switch in splicing from anti- to pro-angiogenic isoforms of
vascular endothelial growth factor. Diabetologia. 48:2422–2427.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rennel E, Waine E, Guan H, Schüler Y,
Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D,
et al: The endogenous anti-angiogenic VEGF isoform, VEGF165b
inhibits human tumour growth in mice. Br J Cancer. 98:1250–1257.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tuxhorn JA, McAlhany SJ, Yang F, Dang TD
and Rowley DR: Inhibition of transforming growth factor-beta
activity decreases angiogenesis in a human prostate cancer-reactive
stroma xenograft model. Cancer Res. 62:6021–6025. 2002.PubMed/NCBI
|
|
19
|
Birukova AA, Cokic I, Moldobaeva N and
Birukov KG: Paxillin is involved in the differential regulation of
endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol.
40:99–107. 2009. View Article : Google Scholar :
|
|
20
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Wever O and Mareel M: Role of tissue
stroma in cancer cell invasion. J Pathol. 200:429–447. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Micke P and Ostman A: Tumour-stroma
interaction: Cancer-associated fibroblasts as novel targets in
anti-cancer therapy? Lung Cancer. 45(Suppl 2): S163–S175. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cébe Suarez S, Pieren M, Cariolato L, Arn
S, Hoffmann U, Bogucki A, Manlius C, Wood J and Ballmer-Hofer K: A
VEGF-A splice variant defective for heparan sulfate and
neuropilin-1 binding shows attenuated signaling through VEGFR-2.
Cell Mol Life Sci. 63:2067–2077. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bates DO, Cui TG, Doughty JM, Winkler M,
Sugiono M, Shields JD, Peat D, Gillatt D and Harper SJ: VEGF165b,
an inhibitory splice variant of vascular endothelial growth factor,
is downregulated in renal cell carcinoma. Cancer Res. 62:4123–4131.
2002.PubMed/NCBI
|
|
25
|
Chen J, Li Z, Zhang S, Zhang R, Dassarath
M and Wu G: Effects of exogenous VEGF(165)b on invasion and
migration of human lung adenocarcinoma A549 cells. J Huazhong Univ
Sci Technolog Med Sci. 31:619–624. 2011. View Article : Google Scholar : PubMed/NCBI
|
